The purpose of this study was to assess population-based real-world safety and effectiveness of the implementation of biosimilar trastuzumab compared to reference trastuzumab, Herceptin, for adjuvant treatment of patients with HER2+ breast cancer in routine practice. Here, ERBB2 is linked to breast carcinoma.